文献速递水电解质与酸碱慢性肾脏病

美国高钾血症的经济负担

The Cost of Hyperkalemia in the United States.
PubMed 文献 · Kidney Int Rep · 2017-11-14

该回顾性分析基于Truven MarketScan索赔数据库,匹配39626例高钾血症患者与对照,发现高钾血症患者30天和1年总医疗费用分别高出4128美元和15983美元,在合并CKD和/或心衰的患者中费用差异更大,且资源利用率更高。

要点

  • 高钾血症患者30天总费用比对照高4128美元,1年高15983美元。
  • 合并CKD和/或心衰者费用差异更大:30天高5553美元,1年高24133美元。
  • 高钾血症患者住院、门诊和急诊利用率均显著更高,住院时间延长1.51天。

核心结论

  • 高钾血症与显著的经济负担相关,对患者和医疗系统均造成较大成本。

研究设计与样本

  • 回顾性分析Truven MarketScan索赔数据库,纳入39626例高钾血症成人患者并按年龄、透析、CKD分期、心衰和RAAS抑制剂使用匹配39626例对照。

主要发现

  • 高钾血症患者30天总医疗费用为5994美元 vs 对照1865美元,差值4128美元(95%CI 3893-4363)。
  • 高钾血症患者1年总医疗费用为31844美元 vs 对照15861美元,差值15983美元(95%CI 15026-16940)。
  • 在11221对合并CKD和/或心衰的匹配患者中,30天费用差5553美元(95%CI 5059-6047),1年差24133美元(95%CI 21748-26518)。
  • 多变量调整后1年总费用差异在所有患者中为15606美元(95%CI 14648-16576),在合并CKD和/或心衰患者中为25156美元(95%CI 23529-26757)。
  • 高钾血症患者资源利用率更高:住院次数30天0.14 vs 0.03、1年0.44 vs 0.19;门诊就诊30天3.33 vs 2.28、1年26.58 vs 18.53;急诊就诊30天0.16 vs 0.06、1年0.86 vs 0.50(均P<0.001)。

临床怎么用

  • 临床应重视高钾血症的经济负担,尤其对合并CKD和/或心衰的高危患者加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are limited data on the cost of hyperkalemia. METHODS: This retrospective analysis of the Truven MarketScan claims database assessed the economic burden of hyperkalemia among selected adult patients with hyperkalemia and matched controls. RESULTS: A total of 39,626 cases (patients with hyperkalemia) were matched to 39,626 controls (patients without hyperkalemia) based on age, dialysis, chronic kidney disease (CKD) stage, heart failure, and renin-angiotensin aldosterone system inhibitor use. Compared with controls, cases incurred $4128 (95% confidence interval [CI] $3893-$4363) higher 30-day total health care costs ($5994 vs. $1865) and $15,983 (95% CI $15,026-$16,940) higher 1-year costs ($31,844 vs. $15,861). Among 11,221 matched pairs of patients with CKD and/or heart failure, cases incurred $5553 (95% CI $5059-$6047) higher 30-day total health care costs ($8165 vs. $2612) and $24,133 (95% CI $21,748-$26,518) higher 1-year costs ($48,994 vs. $24,861) than controls. The multivariable adjusted 1-year total health care cost difference was $15,606 (95% CI $14,648-$16,576) among all patients and $25,156 (95% CI $23,529-$26,757) among patients with CKD and/or heart failure. Cases had higher resource utilization rates including inpatient admissions (30-day: 0.14 vs. 0.03; 1-year: 0.44 vs. 0.19), outpatient visits (30-day: 3.33 vs. 2.28; 1-year: 26.58 vs. 18.53), and emergency department visits (30-day: 0.16 vs. 0.06; 1-year: 0.86 vs. 0.50) (all P < 0.001). When hospitalized, cases stayed 1.51 days (95% CI 1.22-1.80) longer and were 40% more likely to be readmitted. CONCLUSION: These data indicate that hyperkalemia is associated with a significant economic burden on afflicted patients and the health care system.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Betts KA, Woolley JM, Mu F, et al. The Cost of Hyperkalemia in the United States. Kidney Int Rep. 2017. PMID: 29725642. doi:10.1016/j.ekir.2017.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。